Research Progress and New Immunotherapy Strategies of Tumor Microenvironment Metabolism

PENG Yi-man , LUO Xiang-meng, CHEN Jing-yao

Abstract

The tumor microenvironment (TME), the environment of tumorigenesis and tumor progression, incorporates multiple types of cells and non-cellular components. TME plays an important role in tumorigenesis and tumor progression. Due to the abnormal proliferation of tumors, the TME has a unique chemophysiology environment and complex metabolic patterns, which subsequently affects the role of immune cells. Understanding the metabolic patterns of TME can help us develop immunotherapy regimens that target TME. Microbial metabolism and lipid metabolism, the key metabolic processes of TME, have emerged as important foci of research. The metabolites released by the microbiome and the reprogramming of cellular lipid metabolism affect the subsistence of tumor and immune cells. In this review, we summarized the composition and metabolic characteristics of TME and discussed the latest research progress in microbial metabolism and lipid metabolism in TME. We also provided an update on relevant metabolic regulatory targets and immunotherapy strategies, stressing that identifying highly effective therapeutic targets, in spite of the apparent difficulty, is what future research should be focused on.

 

Keywords: Microbial metabolism, Lipid metabolism, Tumor microenvironment, Immunotherapy

 

Full Text:

PDF


References


ANDERSON N M， SIMON M C. The tumor microenvironment. Curr Biol，2020，30(16): R921–R925. doi: 10.1016/j.cub.2020.06.081.

NEJMAN D， LIVYATAN I， FUKS G， et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science，2020，368(6494): 973–980. doi: 10.1126/science.aay9189.

GENG X， CHEN H， ZHAO L， et al. Cancer-associated fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer. Front Cell Dev Biol，2021，9: 655152. doi: 10.3389/fcell.2021.655152.

BARTOSCHEK M， OSKOLKOV N， BOCCI M， et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun，2018，9(1): 5150. doi: 10.1038/s41467-018-07582-3.

SUN H， ZHANG D， HUANG C， et al. Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer. Cancer Biol Med，2021，18(2): 616–630. doi: 10.20892/j.issn.2095-3941.2021.0158.

QUAIL D F， JOYCE J A. Microenvironmental regulation of tumor progression and metastasis. Nat Med，2013，19(11): 1423–1437. doi: 10. 1038/nm.3394.

HANAHAN D， WEINBERG R A. Hallmarks of cancer: the next generation. Cell，2011，144(5): 646–674. doi: 10.1016/j.cell.2011.02.013. HÖCKEL M， VAUPEL P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst，2001，93(4): 266–276. doi: 10.1093/jnci/93.4.266.

IVEY J W， BONAKDAR M， KANITKAR A， et al. Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment. Cancer Lett，2016，380(1): 330–339. doi: 10.1016/j. canlet.2015.12.019.

FISCHER K， HOFFMANN P， VOELKL S， et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood，2007，109(9): 3812–3819. doi: 10.1182/blood-2006-07-035972.

DODARD G， TATA A， ERICK T K， et al. Inflammation-induced lactate leads to rapid loss of hepatic tissue-resident NK cells. Cell Rep，2020， 32(1): 107855. doi: 10.1016/j.celrep.2020.107855.

KOUIDHI S， BEN AYED F， BENAMMAR ELGAAIED A. Targeting tumor metabolism: a new challenge to improve immunotherapy. Front Immunol，2018，9: 353. doi: 10.3389/fimmu.2018.00353.

CHEN Y， SONG Y， DU W， et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci，2019，26(1): 78. doi: 10.1186/s12929-019-0568-z.

O'NEILL L A， KISHTON R J， RATHMELL J. A guide to immunometabolism for immunologists. Nat Rev Immunol，2016，16(9): 553–565. doi: 10.1038/nri.2016.70.

GEIGER R， RIECKMANN J C， WOLF T， et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell， 2016，167(3): 829–842.e13. doi: 10.1016/j.cell.2016.09.031.

MARIGO I， ZILIO S， DESANTIS G， et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell，2016，30(3): 377–390. doi: 10.1016/j.ccell.2016.08.004.

CRONIN S J F， SEEHUS C， WEIDINGER A， et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature，2018， 563(7732): 564–568. doi: 10.1038/s41586-018-0701-2.

PERRONE F， MINARI R， BERSANELLI M， et al. The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors. J Immunother，2020，43(6): 196–203. doi: 10.1097/CJI.0000000000000321.

BLEVE A， DURANTE B， SICA A， et al. Lipid metabolism and cancer immunotherapy: immunosuppressive myeloid cells at the crossroad. Int J Mol Sci，2020，21(16): 5845. doi: 10.3390/ijms21165845.

XUE Q， ROH-JOHNSON M. Sharing is caring. Dev Cell，2019，49(3): 306–307. doi: 10.1016/j.devcel.2019.04.023.

POORE G D， KOPYLOVA E， ZHU Q， et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature，2020， 579(7800): 567–574. doi: 10.1038/s41586-020-2095-1.

JAIN T， SHARMA P， ARE A C， et al. New insights into the cancer-microbiome-immune axis: decrypting a decade of discoveries. Front Immunol，2021，12: 622064. doi: 10.3389/fimmu.2021.622064.

WONG-ROLLE A， WEI H K， ZHAO C， et al. Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell，2021， 12(5): 426–435. doi: 10.1007/s13238-020-00813-8.

GREATHOUSE K L， WHITE J R， VARGAS A J， et al. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol，2018，19(1): 123. doi: 10.1186/s13059-018-1501-6.

MA J， HUANG L， HU D， et al. The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor? J Exp Clin Cancer Res，2021，40(1): 327. doi: 10. 1186/s13046-021-02128-w.

TSAY J J， WU B G， BADRI M H， et al. Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer. Am J Respir Crit Care Med，2018，198(9): 1188–1198. doi: 10.1164/rccm.201710-2118OC.

GUO W， ZHANG Y， GUO S， et al. Tumor microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer. Commun Biol，2021，4(1): 1019. doi: 10.1038/s42003-021-02557-5.

FU A， YAO B， DONG T， et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell，2022，185(8): 1356–1372.e26. doi: 10.1016/j.cell.2022.02.027.

GELLER L T， BARZILY-ROKNI M， DANINO T， et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science，2017，357(6356): 1156–1160. doi: 10.1126/science.aah5043.

HELMINK B A， KHAN M A W， HERMANN A， et al. The microbiome, cancer, and cancer therapy. Nat Med，2019，25(3): 377–388. doi: 10.1038/s41591-019-0377-7.

MIMA K， SUKAWA Y， NISHIHARA R， et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol，2015，1(5): 653–661. doi: 10.1001/jamaoncol.2015.1377.

GUR C， MAALOUF N， SHHADEH A， et al. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1. Oncoimmunology，2019，8(6): e1581531. doi: 10.1080/2162402X.2019. 1581531.

FONG W， LI Q， YU J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene，2020，39(26): 4925–4943. doi: 10.1038/s41388-020-1341-1.

ROUTY B， Le CHATELIER E， DEROSA L， et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science，2018，359(6371): 91–97. doi: 10.1126/science.aan3706.

MATSON V， FESSLER J， BAO R， et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science，2018，359(6371): 104–108. doi: 10.1126/science.aao3290.

ZHENG J H， NGUYEN V H， JIANG S N， et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med，2017，9(376): eaak9537.


Refbacks

  • There are currently no refbacks.